Shanghai Junshi Biosciences (SEHK:1877) has just paired fresh earnings with important clinical news. Nine-month sales reached CNY 2,513.41 million, while the net loss narrowed to CNY 149.2 million.
The latest earnings and clinical results have not stopped selling pressure, with Shanghai Junshi Biosciences' share price at HK$15.26 after a 1-day share price return of a 3.9% decline and a year-to-date share price return down 31.5%. The 1-year total shareholder return has fallen 42.6%, which points to fading momentum despite the NEOTORCH data and the launch of the new JS203 Phase 3 trial.
Scan for other healthcare developers with similar clinical momentum and clearer share price trends by checking out the hand-picked 125 healthcare AI stocks alongside Shanghai Junshi Biosciences.
Bulls point to Shanghai Junshi Biosciences' growing sales and clinical progress, while bears highlight ongoing losses and a share price that keeps sliding. Which side does the current valuation really support?
Preferred Price-to-Sales of 4.1x: Is it justified?
On simple numbers, Shanghai Junshi Biosciences looks cheap. The stock last closed at HK$15.26, while the SWS framework flags the shares as trading at good value compared with both peers and an internal fair-value range.
The preferred lens here is the price-to-sales ratio, or P/S. This metric compares the company's market value to its annual revenue and is often used for drug developers that are still loss-making but already generating meaningful product sales.
Shanghai Junshi Biosciences is currently valued at 4.1x sales. That multiple is described as good value versus both the Hong Kong Biotechs peer average of 8.2x and the broader industry average of 7.7x. The SWS fair P/S estimate for the stock is 8.1x. This indicates that the current market level is materially lower than a ratio the market could move towards if sentiment or fundamentals line up.
Relative pricing looks even starker in that context. The stock trades at roughly half the peer and sector P/S levels, and at a discount to the 8.1x fair ratio that the SWS model indicates for Shanghai Junshi Biosciences.
Explore the SWS fair ratio for Shanghai Junshi Biosciences.
Result: Price-to-Sales of 4.1x (UNDERVALUED)
Still, the Shanghai Junshi Biosciences story can break if key Phase 3 assets stumble or if ongoing losses persist and put pressure on funding options.
Find out about the key risks to this Shanghai Junshi Biosciences narrative .
Another View on Shanghai Junshi Biosciences: DCF points to deeper upside
On a second check, the SWS DCF model paints an even stronger picture for Shanghai Junshi Biosciences. With the share price at HK$15.26 and the future cash flow value estimated at HK$61.58, the stock is described as trading about 75.2% below that DCF fair value. This suggests a much wider gap than the 4.1x P/S implies. If both approaches flag value, how comfortable are you with the assumptions that sit underneath a biotech cash flow model?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out Shanghai Junshi Biosciences for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 204 high quality undervalued stocks . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Plenty in this Shanghai Junshi Biosciences story looks optimistic, and plenty looks risky, so act while sentiment is mixed and test the numbers yourself. To see what the market-friendly strengths might be, start with the 4 key rewards .
Looking for more investment ideas beyond Shanghai Junshi Biosciences?
If Shanghai Junshi Biosciences has your attention, do not stop here. Use focused stock lists to identify additional opportunities.
-
Target potential mispricing by scanning companies that screen as attractively valued on quality and fundamentals through the 204 high quality undervalued stocks .
-
Build a sturdier core by reviewing a list of solid balance sheet and fundamentals (199 results) that can help support resilience when conditions change.
-
Explore a set of 614 high quality undiscovered gems that combine strong fundamentals with lower mainstream attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 1877.HK .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
